Friday, Agios Pharmaceuticals, Inc. (AGIO) announced its decision to discontinue the study of tebapivat, a next-generation oral pyruvate kinase activator designed to provide optimized clinical benefits for patients with rare hematologic diseases.
The decision comes as results from its Phase 2b trial that did not meet the company's predefined threshold to support further development in this indication.
While tebapivat demonstrated evidence of biological activity, clinical benefit was not observed in a sufficient proportion of patients or subgroup of patients during the study.
The company expects to share topline data from this Phase 2 trial in the second half of 2026.
In the pre-market hours, AGIO is falling 5.45 percent, to $28.76 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.